Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Xencor / XmAb717-06

Trial Overview

Official Title

Aphase 1b/2 Open Label, Randomized Study of Vudalimab in Combination With Chemotherapy or Pembrolizumab In Combination With Chemotherapy as First Line Treatment In Patients with Advanced Non-Small Lung Cancer

 

Study Purpose

To find a safe, tolerable, and recommended dose of vudalimab for people with locally advanced (unresectable) or metastatic NSCL when combine with chemotherapy.

Diagnosis

Locally Advanced (unresectable) or metastatic non-squamous non-small lung cancer

Eligibility

Histologically confirmed, locally advanced (unresectable) or metastatic NSCL

 

No prior systemic therapy for advanced/metastatic NSCLC > 12 months prior to development of metastatic disease.

 

No central nervous system metastatic disease.

 

No significant autoimuune disease.

Intervention

 

Treatement arm 1:

Vudalimab with chemotherapy (carboplatin & Pemetrexed)

For more information, go to the link below:

 

https://clinicaltrials.gov/study/NCT06173505?term=XmAb717-06&rank=1

 

Key Participation Requirements
Trial Location(s)
Methodist Estabrook Cancer Center
Gender
Male or Female
Age
19 and older
Enrollment Status
Recruiting
Methodist Health System Trial Code
XmAb717-06